Shopping Cart
- Remove All
- Your shopping cart is currently empty
PaPE-1 is a pathway-preferential estrogen that activates extracellular nuclear signaling pathways without affecting nuclear signaling pathways. It exerts anti-apoptotic effects by inhibiting Aβ-induced caspase activity and reducing chromatin condensation associated with apoptosis, thereby preventing neuronal cell death. Additionally, post-treatment with PaPE-1 decreases the mRNA expression of apoptosis-specific factors (such as Bax, Gsk3b, Fas, and Fasl) under Aβ influence, while upregulating Bcl2 expression.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | PaPE-1 is a pathway-preferential estrogen that activates extracellular nuclear signaling pathways without affecting nuclear signaling pathways. It exerts anti-apoptotic effects by inhibiting Aβ-induced caspase activity and reducing chromatin condensation associated with apoptosis, thereby preventing neuronal cell death. Additionally, post-treatment with PaPE-1 decreases the mRNA expression of apoptosis-specific factors (such as Bax, Gsk3b, Fas, and Fasl) under Aβ influence, while upregulating Bcl2 expression. |
Alias | pathway Preferential Estrogen, PaPE1, PaPE 1 |
Molecular Weight | 254.32 |
Formula | C17H18O2 |
Cas No. | 2107327-36-4 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.